Hiroiku Kawakami Selected Research

RNA (Ribonucleic Acid)

10/2013	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.
6/2009	Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients.
1/2006	Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroiku Kawakami Research Topics

Disease

4	Chronic Hepatitis B 01/2019 - 05/2007
3	Chronic Hepatitis C 02/2015 - 01/2006
1	Hepatitis 10/2013
1	Hepatitis C 06/2009
1	Infections 05/2007
1	Hemolytic Anemia 01/2007

Drug/Important Bio-Agent (IBA)

3	InterferonsIBA 01/2019 - 02/2015
3	NucleotidesIBA 01/2019 - 10/2013
3	NucleosidesIBA 01/2019 - 05/2007
3	Ribavirin (Virazole)FDA LinkGeneric 02/2015 - 01/2007
3	RNA (Ribonucleic Acid)IBA 10/2013 - 01/2006
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 01/2018
2	AntigensIBA 01/2019 - 01/2018
2	Hepatitis B e AntigensIBA 01/2018 - 10/2013
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	nasIBA 10/2013
1	Lamivudine (Epivir)FDA Link 05/2007
1	lipoarabinomannan (LAM)IBA 05/2007
1	Eicosapentaenoic AcidIBA 01/2007
1	Interferon-alpha (Interferon Alfa)IBA 01/2007

Therapy/Procedure

6	Therapeutics 01/2019 - 01/2007